Lenacapavir (Sunlenca) (tabs and injection)

Status:
Do Not Prescribe (DNP)
Decision Date:
November 2022
 

Comments

Use in combination with other antiretroviral(s) for the treatment of adults with multidrugresistant HIV1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen 

Do Not Prescribe (DNP) Drug Classifications

  • 2: Have a lack of data on safety compared with standard therapy
  • 4: Have a lack of data on cost-effectiveness compared with standard therapy
  • 5: Less cost-effective than current standard therapy

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app